

Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. – 20. (Cancelled)

21. (Previously Presented) A dimerized fusion polypeptide comprising a first polypeptide operably linked to a second polypeptide, wherein the first polypeptide:

(a) comprises a P-selectin glycoprotein ligand-1; and

(b) is glycosylated by an α 1,3 galactosyltransferase and the second polypeptide comprises an immunoglobulin Fc region.

22. (Previously Presented) The fusion polypeptide of claim 21, wherein the first polypeptide comprises multiple Gal α 1, 3Gal epitopes.

23. (Previously Presented) The fusion polypeptide of claim 21, wherein the α 1,3 galactosyltransferase is porcine.

24. – 25. (Cancelled)

26. (Canceled)

27. (Cancelled)

28. (Canceled)

29.- 31. (Canceled)

32.-33. (Canceled)

U.S.S.N 09/194,396
Holgersson et al.

34.-36. (Canceled)

37.- 38. (Canceled)